XELOX stop-and-go trial:A phase 2 study of 1st line chemotherapy for unresectable or recurrent colorectal cancer.

ABSTRACT: Interventions: XELOX therapy 6 courses, followed by XELODA 6 courses, then XELOX Primary outcome(s): Progression free survival Study Design: Single arm Non-randomized

DISEASE(S): Unresectable Or Recurrent Colorectal Cancer

PROVIDER: 2620630 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR